Trade Agreements and Pharmaceutical Patent Protection: Implications for the Governance over Pharmaceutical Products in Canada
DOI:
https://doi.org/10.25071/1929-8404.34702Abstract
This paper was prepared for a course on Canadian health policy. Its purpose is to expose the harmful ramifications of international trade agreements on the pharmaceutical market in Canada and the governance surrounding this market. This paper will explore the various implications that trade agreements have on the affordability of drugs, the strength of intellectual property protection, and the transfer of authority and influence from government to “Big Pharma.” This paper will unravel the reality that trade agreements are not beneficial to the Canadian people looking to access an affordable pharmaceutical market, but rather, act quite contrary to this. Facts will show that trade agreements work to put money into the pockets of large brand-name pharmaceutical companies in the forms of billions of dollars of revenue and profit. This paper will encourage readers to question the feasibility of extending patent legislation for brand-name pharmaceutical products, the increasing role of trade agreements and the pharmaceutical industry in Canada, and the substitutability of brand-name drugs over cheaper generic alternatives.References
Abbot, F. (2006). The Cycle of Action and Redaction: Developments and Trends in Intellectual Property and Health. In P. Roffe, G. Tansey & D. Vivas-Eugui (Eds.), Negotiating Health: Intellectual Property and Access to Medicines (27-40). London: Earthscan.
Armstrong, P. & Armstrong, H. (1991). Health Care as a Business: The legacy of free trade. Ottawa: Canadian Centre for Policy Alternatives.
Canadian Institute for Health Information. (2010). Drug Expenditure in Canada, 1985-2010 [Data file]. Retrieved from http://secure.cihi.ca/cihiweb/products/drug_expenditure_2010_en.pdf
Grieshaber-Otto, J. & Sinclair, S. (2004). Key trade treaty rules and health safeguards. In Bad Medicine (chapter 2). Retrieved from http://www.policyalternatives.ca/sites/default/files/uploads/publications/National_Office_Pubs/bad_medicine.pdf
Grootendorst, P. (2009). Patents, public-private partnerships or prizes: How should we support pharmaceutical innovation? Hamilton, ON: Program for Research on Social and Economic Dimensions of an Aging Population, McMaster University.
Grootendorst, P. & Hollis, A. (2011, February 7). The Canadian-European Union Comprehensive Economic & Trade Agreement: An economic impact assessment of proposed pharmaceutical intellectual property provisions. Retrieved from http://www.canadiangenerics.ca/en/news/docs/02.07.11CETAEconomicImpactAssessment-FinalEnglish.pdf
Hore, E. (2004). Patently absurd: Evergreening of pharmaceutical patent protection under the patented medicines (Notice of Compliance) regulations of Canada's Patent Act. Toronto, ON: Canadian Generic Pharmaceutical Association.
Lanjouw, J. (2005). Patents, Price Controls and Access to New Drugs: How policy affects global market entry (National Bureau of Economic Research Working Paper 11321).
Lexchin, J. (1992). Pharmaceuticals, patents and politics: Canada and Bill C-22. Ottawa, ON: The Canadian Centre for Policy Alternatives.
Lexchin, J. (2001). Globalization, trade deals and drugs: Heads the industry wins, tails Canada loses. Canadian Centre for Policy Alternatives Briefing Paper Series: Trade and Investment, 2(8). Retrieved from http://www.policyalternatives.ca/sites/default/files/uploads/publications/National_Office_Pubs/brief2_8.pdf
Lexchin, J. (2005). Intellectual property rights and the Canadian pharmaceutical marketplace: where do we go from here? International Journal of Health Services, 35(5), 237-56.
Permanand, G. & Altenstetter, C. (2004). The politics of pharmaceuticals in the European Union. In E. Mossialos, M. Mrazek & T. Walley (Eds.), Regulating pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (38-54). Maidenhead: Open University Press.
Pazderka, B. (1999). Patent Protection and Pharmaceutical R&D Spending in Canada. Canadian Public Policy, 25(1), 29-46.
Picard, A. (2011, February 7). EU trade deal could cost Canadian drug plan billions. The Globe and Mail. Retrieved from http://www.theglobeandmail.com/life/health/eu-trade-deal-could-cost-canadian-drug-plans-billions/article1896747/
Romanow, R. J. (2002) Building on Values: The Future of Health Care in Canada. Saskatoon: Commission on the Future of Health Care in Canada.
Smith, M. (2000). Patent protection for pharmaceutical products in Canada: Chronology of significant events. Retrieved from Library of Parliament, Parliamentary Research Branch: http://dsp-psd.communication.gc.ca/Collection-R/LoPBdP/BP/prb9946-e.htm
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).